Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2002 June;54(2) > Minerva Urologica e Nefrologica 2002 June;54(2):145-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

THERAPEUTICAL NOTES   

Minerva Urologica e Nefrologica 2002 June;54(2):145-8

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: Italian

Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors

Morale W., Puliatti C., Veroux P., Veroux M., Valvo C., Cappello D., Puliatti D., Francesco L.

Policlinico Università di Catania Centro Trapianti di Rene - I Clinica Chirurgica *Cattedra di Chirurgia Sostitutiva e dei Trapianti di Organo - Catania


PDF


Back­ground. ­Post kid­ney trans­plan­ta­tion eryth­ro­cy­to­sis is a fre­quent com­pli­ca­tion in ­male sub­jects. In our expe­ri­ence, it ­occurs in approx­i­mate­ly 20% of trans­plant ­patients receiv­ing cyclo­spo­rine immu­no­sup­pres­sion ther­a­py.
Meth­ods. Twen­ty-two ­patients ­with ­post kid­ney trans­plan­ta­tion eryth­ro­cy­to­sis ­were treat­ed ­using ACE-inhib­i­tors (lisin­o­pril) at a ­dose of 2-5-5 mg/day for a ­mean peri­od of 15 ­months. ­Owing to the ­onset of col­lat­er­al ­effects, 27% of ­these ­patients request­ed the con­ver­sion of ACE ­into angio­ten­sin II recep­tor antag­o­nists (AII). Twen­ty out of 22 ­patients ­were ­male (90%).
­Results. Treat­ment result­ed in a 15% reduc­tion of hem­a­toc­rit val­ues com­pared to ­basal lev­els, ­which ­remained ­stable ­over ­time. No col­lat­er­al ­effects ­were record­ed, ­either for the kid­neys or in ­terms of hypo­ten­sion.
Con­clu­sions. ACE-inhib­i­tors (lisin­o­pril) or alter­na­tive­ly the use of angio­ten­sin II recep­tor antag­o­nists, ­like iosar­tan, at low dos­es, is an effec­tive and ­safe treat­ment for ­patients devel­op­ing ­post-trans­plan­ta­tion eryth­ro­cy­to­sis (PTE).

top of page